Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome 2022-01-25 09:00
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021 2021-12-15 09:35
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment 2021-12-03 13:45
1 2 3